Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Raltegravir (Primary)
- Indications HTLV-I infections
- Focus Therapeutic Use
- 19 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Oct 2018.
- 13 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.